Medicare cracks down on PBM middlemen: forced transparency, affiliate disclosure, and pharmacy acces
S. 882 — Patients Before Middlemen Act · Filed by Marsha Blackburn (R-TN) · 7 cosponsors · Introduced Mar 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare prescription drug plans to accept any pharmacy meeting standard contract terms ("any willing provider"), establishes federal standards for what constitutes reasonable contract terms by 2028, and imposes strict transparency and accountability rules on pharmacy benefit managers (PBMs). PBMs must disclose detailed drug pricing, rebate arrangements, and affiliate relationships; cannot profit from sources other than flat-fee services; and face enforcement through civil penalties and disgorgement of improper payments. Independent pharmacies and small chains benefit from reduced network exclusion; Medicare beneficiaries gain visibility into drug costs and PBM conflicts of interest.
Why we flagged it
The bill's core mechanism is regulatory constraint on PBM profit-taking and information asymmetry, not a subsidy or carve-out. It mandates disclosure, restricts self-dealing, and creates enforcement pathways—classic accountability legislation. The 'Patients Before Middlemen' title accurately reflects the functional intent.
What the text implies
- PBMs may respond by consolidating further or shifting costs to plan sponsors via higher service fees (which are permitted if flat-rate and fair-market-value). The bill does not cap fees, only requires transparency and bona-fide-service justification.
- The 'essential retail pharmacy' definition and reporting regime may create a two-tier system: protected pharmacies in underserved areas receive preferential treatment, while urban/suburban chains face network exclusion pressure. This could fragment pharmacy networks.
The full analysis lists 5 implications of this text.
Who stands to gain
independent pharmacies and small pharmacy chains (reduced network exclusion, access to contracts); Medicare beneficiaries (lower out-of-pocket costs if PBM rebates are passed through; visibility into; generic drug manufacturers (formulary bias against generics will be exposed and challenged)